
UV / IR
LightLab Sweden's New UV Light Disinfection Technology Outperforms Conventional UV-Technology
Swedish cleantech company LightLab Sweden is introducing a new UVC disinfection technology called PureFize®, proven to inactivate bacteria and viruses, among them SARS-CoV-2. To test its effectiveness, LightLab Sweden partnered with SAES Group and the University of Siena, Italy. To proof the…

The study was conducted by the University of Siena and will be submitted for publication in a peer reviewed journal of public health. The study shows that PureFize is effective in inactivating 99.9% (log3) of the SARS-CoV-2 virus in the samples in less than three minutes and 99.9999% (log6) in less than ten minutes. This is the first time a scientific study has been conducted and published using a prototype of a real consumer product for UVC disinfection of surfaces.
"We are happy to present the first scientific evidence of this UVC disinfection technology. A very good result was obtained to inactivate SARS-CoV-2 by the tested prototype of a real consumer product. The PureFize UVC technology can play an important role in inactivating SARS-CoV-2 from objects in everyday life, says Professor Gabriele Messina, MD, Associate Professor in General and Applied Hygiene (Public Health), University of Siena, Italy.
The PureFize UVC disinfection technology is a completely new and sustainable technology developed by the Swedish cleantech company LightLab Sweden. PureFize has been developed to utilize a wider and more effective wavelength spectrum to inactivate bacteria and viruses. The PureFize technology is fast, effective and generates minimal thermal heating, making it energy efficient. It does not contain any mercury or chemicals and does not generate ozone.
"I am very proud that we now can present PureFize. Many companies on the market state that their products inactivate SARS-CoV-2 from surfaces, but few have actually conducted scientific tests with their products. Scientific validation is something that is very important for us. The effectiveness of PureFize has now been validated by the University of Siena. PureFize makes it possible to bring UVC into everyday life in a safe and sustainable way. We aim to raise the standard for UVC disinfection and show that PureFize can be effective in inactivating bacteria and viruses but also sustainable in minimizing the impact of the technology on the environment," says Rune Torbjörnsen, CEO at LightLab Sweden.
The PureFize technology is now being extensively launched and is ready to be shipped globally. The technology offers vast integration opportunities and can be used in a wide range of applications and installed in products without major redesigns or adaptations. LightLab Sweden has several ongoing projects with partners who want to integrate effective and sustainable UVC solutions into their products to provide added value to customers and consumers. PureFize is protected by 96 granted patents and another 47 patent applications are awaiting approval.
"This is just the first step for us in raising the bar on disinfection through UVC technology and proving that the PureFize technology is effective on bacteria and viruses. We will continue to explore the many possibilities to apply this technology to secure a healthier and safer everyday life, says Fredrik Forssell, CMO, LightLab Sweden.
About the Study:
The University of Siena has tested a new UVC technology called PureFize that is developed by LightLab Sweden. During the study the PureFize UVC light sources were placed in a surface disinfection box developed by LightLab Sweden for general demonstration purposes. Six PureFize light sources where used at a distance of > 7,5 cm from the Sars-Cov-2 samples. The sample was a solution containing SARS COV-2 at a concentration 107,2 *TCID50%/ml, where TCID50% means a virus concentration such as to induce damage on 50% of infected cells. The result was a reduction of 99.9% (log3) of the virus in the samples in less than three minutes and 99.9999% (log6) in less than ten minutes.
Details on the study are available from Prof. Gabriele Messina, MD, Associate Professor, University of Siena, Italy - gabriele.messina@unisi.it








